Oncotarget

Research Papers: Pathology:

Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth

Marco Pizzi, Francesco Piazza _, Claudio Agostinelli, Fabio Fuligni, Pietro Benvenuti, Elisa Mandato, Alessandro Casellato, Massimo Rugge, Gianpietro Semenzato and Stefano A. Pileri

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:6544-6552. https://doi.org/10.18632/oncotarget.3446

Metrics: PDF 1359 views  |   HTML 1477 views  |   ?  


Abstract

Marco Pizzi1,*, Francesco Piazza2,3*, Claudio Agostinelli4, Fabio Fuligni4, Pietro Benvenuti1, Elisa Mandato2,3, Alessandro Casellato2,3, Massimo Rugge1, Gianpietro Semenzato2,3 and Stefano A. Pileri4

1 Department of Medicine, Surgical Pathology and Cytopathology Unit, DIMED University of Padua, Padua, Italy

2 Department of Medicine, Hematology and Clinical Immunology Branch, DIMED University of Padua, Padua, Italy

3 Venetian Institute of Molecular Medicine (VIMM), Padua, Italy

4 Department of Experimental, Hematopathology and Hematology Sections, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

* These authors have contributed equally to this work

Correspondence to:

Francesco Piazza, email:

Keywords: CK2, Non-Hodgkin Lymphoma, CX-4945, B-cell

Received: January 11, 2015 Accepted: January 28, 2015 Published: January 31, 2015

Abstract

Serine-threonine kinase CK2 is highly expressed and pivotal for survival and proliferation in multiple myeloma, chronic lymphocytic leukemia and mantle cell lymphoma. Here, we investigated the expression of α catalytic and β regulatory CK2 subunits by immunohistochemistry in 57 follicular (FL), 18 Burkitt (BL), 52 diffuse large B-cell (DLBCL) non-Hodgkin lymphomas (NHL) and in normal reactive follicles. In silico evaluation of available Gene Expression Profile (GEP) data sets from patients and Western blot (WB) analysis in NHL cell-lines were also performed. Moreover, the novel, clinical-grade, ATP-competitive CK2-inhibitor CX-4945 (Silmitasertib) was assayed on lymphoma cells. CK2 was detected in 98.4% of cases with a trend towards a stronger CK2α immunostain in BL compared to FL and DLBCL. No significant differences were observed between Germinal Center B (GCB) and non-GCB DLBCL types. GEP data and WB confirmed elevated CK2 mRNA and protein levels as well as active phosphorylation of specific targets in NHL cells. CX-4945 caused a dose-dependent growth-arresting effect on GCB, non-GCB DLBCL and BL cell-lines and it efficiently shut off phosphorylation of NF-κB RelA and CDC37 on CK2 target sites. Thus, CK2 is highly expressed and could represent a suitable therapeutic target in BL, FL and DLBCL NHL.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3446